- $473.31m
- $549.31m
- $170.44m
U.S. STOCKS ON THE MOVE-Regenxbio, Repay, Natera, Fortune Brands
U.S. STOCKS ON THE MOVE-Regenxbio, Repay, Natera, Fortune Brands
Regenxbio rises on $100 million AbbVie milestone for eye disease drug
Brief: Regenxbio - Completes Dosing In Rgx-202 Confirmatory Study
U.S. STOCKS ON THE MOVE-Abbvie, AMC, Getty
U.S. STOCKS ON THE MOVE-Getty Images, Ecarx, Maplight Therapeutics
U.S. STOCKS ON THE MOVE-Definium, Regenxbio, Arcosa
U.S. STOCKS ON THE MOVE- Visteon, Incyte, Apogee
Brief: Regenxbio Aligns With FDA For Potential Accelerated Approval Of NAVSUNLI
Regenxbio rises after report FDA to reverse rejection of rare-disease gene therapy
US FDA reverses course on Regenxbio's rare-disease gene therapy, backs accelerated approval bid (updated)
FDA to reverse rejection of Regenxbio's rare-disease drug, WSJ reports
Brief: FDA Will Reverse Rejection Of Third Rare-Disease Drug, Regenxbio Says- WSJ
U.S. STOCKS ON THE MOVE-Advanced Energy, Bel Fuse, Cerebras
U.S. STOCKS ON THE MOVE-Klarna, Biogen, Legence
Regenxbio falls after late-stage data for muscle disorder therapy
Regenxbio Q1 revenue drops sharply, posts net loss
Regenxbio's muscle disorder therapy meets main goal in late-stage study (updated)
Regenxbio's muscle disorder therapy meets main goal in late-stage study